COMMUNIQUÉS West-GlobeNewswire

Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
08/06/2026
MINNEAPOLIS and BRISBANE, Australia, June 08, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory [...]
Virbac : Declaration of the number of shares and voting rights 05/2026
08/06/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote 05/2026
08/06/2026
DÉCLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program
08/06/2026
Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is August 3, 2026 SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, [...]
Standard BioTools and Treeline Biosciences Announce Merger Agreement
08/06/2026
Combined company to operate as Treeline Biosciences, advancing a deep pipeline of small molecule inhibitors, protein degraders and targeted therapy antibody-drug conjugates Company to be led by Treeline CEO and co- [...]
Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA
08/06/2026
MIPLYFFA patent submitted for Orange Book listing, with patent protection to 2041 Separately filed patent term extension remains pending with the U.S. Patent and Trademark Office BOSTON, June 08, 2026 (GLOBE NEWSWIRE [...]
Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission
08/06/2026
European regulatory filing supports planned 2026 initiation of Phase 2b study of Teverelix® in an underserved population representing ~$4 billion annual market opportunity PHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE [...]
Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal
08/06/2026
BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW) , a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary [...]
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
08/06/2026
REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, [...]
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
08/06/2026
REYKJAVIK, Iceland, June 8, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that [...]
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
08/06/2026
Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible urticaria, to be highlighted in late-breaker oral presentation New Phase IIIb REMIXED extension data in chronic [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
08/06/2026
COPENHAGEN, Denmark, June 8, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on June 2, 2026, under which the Company will repurchase shares for an amount up to [...]
Virbac: modalités de mise à disposition ou de consultation des documents préparatoires à l'assemblée générale mixte du 29 juin 2026
08/06/2026
Les actionnaires de la société VIRBAC sont invités à participer à l’assemblée générale mixte qui se tiendra le lundi 29 juin 2026 à 14 heures , dans les bâtiments de VIRBAC direction, 13 ème rue LID 06517 Carros. L’avis [...]
Intravacc Highlights Integrated Analytical Capabilities to Accelerate Vaccine and Biologics Development
08/06/2026
Advanced analytical services support partners from product characterization and assay development to GMP readiness and clinical manufacturing Intravacc offers state-of-the-art analytical methods for identity, content, [...]
Intravacc met en avant ses capacités analytiques intégrées destinées à accélérer le développement de vaccins et de produits biologiques
08/06/2026
Ses services analytiques de pointe accompagnent les partenaires à chaque étape, de la caractérisation des produits et du développement des tests à la mise en conformité aux BPF et à la fabrication clinique Intravacc [...]
Amphista Therapeutics announces FDA clearance of IND application for AMX-883, its lead Targeted Glue™ degrader for acute myeloid leukaemia
08/06/2026
Amphista to initiate its first clinical trial for AMX-883, a potent, orally bioavailable DCAF16-dependent degrader of BRD9, for acute myeloid leukaemia (AML) in H2 2026 The Phase 1 monotherapy dose-escalation and [...]
Reminder: Nicox June 2024 Warrants will expire June 19, 2026
08/06/2026
Press Release Reminder: Nicox June 2024 Warrants will expire June 19, 2026 June 8, 2026 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international [...]
Rappel : les BSA Nicox de juin 2024 expireront le 19 juin 2026
08/06/2026
Communiqué de presse Rappel : les BSA Nicox de juin 2024 expireront le 19 juin 2026 8 juin 2026 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), une [...]
Vivoryon Therapeutics N.V. to Report Q1 2026 Financial Results on June 11, 2026
08/06/2026
Vivoryon Therapeutics N.V. to Report Q1 2026 Financial Results on June 11, 2026 Halle (Saale) / Munich, Germany, June 8, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical [...]

Pages